ImmunoPrecise Antibodies Ltd (IPA)
0.4599
-0.02
(-4.19%)
USD |
NASDAQ |
Nov 14, 16:00
0.50
+0.04
(+8.72%)
After-Hours: 20:00
ImmunoPrecise Antibodies Net Income (Quarterly): -2.920M for July 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2024 | -2.920M |
| April 30, 2024 | -13.29M |
| January 31, 2024 | -2.177M |
| October 31, 2023 | -1.930M |
| July 31, 2023 | -2.558M |
| April 30, 2023 | -3.782M |
| January 31, 2023 | -3.484M |
| October 31, 2022 | -5.523M |
| July 31, 2022 | -7.283M |
| April 30, 2022 | -3.663M |
| January 31, 2022 | -3.019M |
| October 31, 2021 | -3.983M |
| July 31, 2021 | -2.628M |
| April 30, 2021 | -3.995M |
| January 31, 2021 | -1.005M |
| October 31, 2020 | -0.3509M |
| July 31, 2020 | -0.4013M |
| April 30, 2020 | -0.688M |
| January 31, 2020 | -0.4755M |
| October 31, 2019 | -1.030M |
| July 31, 2019 | -1.515M |
| April 30, 2019 | -2.885M |
| January 31, 2019 | -0.891M |
| October 31, 2018 | -1.140M |
| July 31, 2018 | -0.845M |
| Date | Value |
|---|---|
| April 30, 2018 | -1.726M |
| January 31, 2018 | -0.9577M |
| October 31, 2017 | -0.7221M |
| July 31, 2017 | -0.649M |
| April 30, 2017 | -0.8996M |
| January 31, 2017 | -3.327M |
| September 30, 2016 | -0.0036M |
| June 30, 2016 | -0.0072M |
| March 31, 2016 | -0.0031M |
| December 31, 2015 | -0.0299M |
| September 30, 2015 | -0.0022M |
| June 30, 2015 | 0.0067M |
| March 31, 2015 | 0.0022M |
| December 31, 2014 | -0.0137M |
| September 30, 2014 | -0.0269M |
| June 30, 2014 | 0.0013M |
| March 31, 2014 | -0.0171M |
| December 31, 2013 | -0.0437M |
| September 30, 2013 | 0.14M |
| June 30, 2013 | -0.0122M |
| March 31, 2013 | -0.0176M |
| December 31, 2012 | -0.0635M |
| September 30, 2012 | -0.0175M |
| June 30, 2012 | -0.0015M |
| March 31, 2012 | -0.0139M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-13.29M
Minimum
Apr 2024
-0.3509M
Maximum
Oct 2020
-3.324M
Average
-2.920M
Median
Jul 2024
Net Income (Quarterly) Benchmarks
| Aurinia Pharmaceuticals Inc | 14.35M |
| Edesa Biotech Inc | -1.668M |
| Lexaria Bioscience Corp | -1.782M |
| Xenon Pharmaceuticals Inc | -57.92M |
| ESSA Pharma Inc | -7.234M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.842M |
| Total Expenses (Quarterly) | 7.220M |
| EPS Diluted (Quarterly) | -0.1095 |
| Enterprise Value | 11.89M |
| Gross Profit Margin (Quarterly) | 44.77% |
| Profit Margin (Quarterly) | -75.98% |
| Earnings Yield | -169.7% |
| Normalized Earnings Yield | -82.88 |